United Therapeutics (NASDAQ:UTHR) EVP Sells $4,671,406.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $562.82, for a total value of $4,671,406.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $25,423,705.04. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Trading Up 0.3%

UTHR stock traded up $1.94 during trading on Thursday, reaching $565.87. 418,827 shares of the stock were exchanged, compared to its average volume of 477,460. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The company has a market capitalization of $24.02 billion, a P/E ratio of 20.89, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60. The stock has a 50 day simple moving average of $562.18 and a 200-day simple moving average of $510.32.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period last year, the business earned $6.63 earnings per share. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. Equities analysts predict that United Therapeutics Corporation will post 27.07 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on UTHR. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Finally, UBS Group raised their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Torren Management LLC bought a new position in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in United Therapeutics during the fourth quarter worth about $31,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.